MLAB Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 107498 min ago

@ $92.30

Ausgestellt: 14 Feb 2024 @ 15:40

Rendite: 11.80%

Vorheriges Signal: Feb 13 - 15:30

Vorheriges Signal: Kaufen

Rendite: 0.53 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally...

Stats
Tagesvolumen	18 627.00
Durchschnittsvolumen	43 153.00
Marktkapitalisierung	556.61M
EPS	$0 ( 2024-02-05 )
Nächstes Ertragsdatum	( $2.33 ) 2024-05-24
Last Dividend	$0.160 ( 2023-11-29 )
Next Dividend	$0 ( N/A )
P/E	607.00
ATR14	$0.499 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Sullivan John James	Sell	450	Non Qualified Stock Option
2024-04-02	Sakys John	Sell	2 500	Non Qualified Stock Option
2024-04-02	Owens Gary M	Sell	5 000	Non Qualified Stock Options
2024-04-02	Archbold Brian David	Sell	420	Non Qualified Stock Option
2024-01-08	Archbold Brian David	Sell	290	Non Qualified Stock Option

INSIDER POWER
12.65
Last 100 transactions
Buy: 73 301 \| Sell: 52 584

Mesa Laboratories Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Mesa Laboratories Inc Finanzdaten

Annual	2023
Umsatz:	$219.08M
Bruttogewinn:	$133.69M (61.02 %)
EPS:	$0.170

FY	2023
Umsatz:	$219.08M
Bruttogewinn:	$133.69M (61.02 %)
EPS:	$0.170

FY	2022
Umsatz:	$184.34M
Bruttogewinn:	$109.09M (59.18 %)
EPS:	$0.360

FY	2021
Umsatz:	$133.94M
Bruttogewinn:	$87.01M (64.97 %)
EPS:	$0.660

Financial Reports:

No articles found.

Mesa Laboratories Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.160 (N/A)	$0.160 (N/A)	$0.160 (N/A)	$0.160 (N/A)	$0.160 (N/A)	$0.160 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Mesa Laboratories Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 7.61 - good (76.09%) | Divividend Growth Potential Score: 5.87 - Stable (17.38%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.200	2003-11-26
Last Dividend	$0.160	2023-11-29
Next Dividend	$0	N/A
Payout Date	2023-12-15
Next Payout Date	N/A
# dividends	81	--
Total Paid Out	$11.06	--
Avg. Dividend % Per Year	0.19%	--
Score	4.41	--
Div. Sustainability Score	7.61
Div.Growth Potential Score	5.87
Div. Directional Score	6.74	--

Next Divdend (Est)
(2024-07-01)

$0.164 Estimate 39.63 %

Dividend Stability

0.79 Good

Dividend Score

4.41

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2003	$0.200	3.07%
2004	$0.410	4.07%
2005	$0.500	3.85%
2006	$0.390	2.60%
2007	$0.340	1.80%
2008	$0.400	1.54%
2009	$0.410	2.27%
2010	$0.450	1.70%
2011	$0.490	1.63%
2012	$0.530	1.29%
2013	$0.570	1.08%
2014	$0.610	0.79%
2015	$0.640	0.80%
2016	$0.640	0.64%
2017	$0.640	0.52%
2018	$0.640	0.51%
2019	$0.640	0.31%
2020	$0.640	0.26%
2021	$0.640	0.23%
2022	$0.640	0.20%
2023	$0.640	0.37%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00445	1.500	9.91	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00128	1.200	9.96	10.00	[0 - 0.3]
returnOnEquityTTM	0.00241	1.500	-1.084	-1.626	[0.1 - 1]
payoutRatioTTM	3.63	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	2.68	0.800	1.606	1.285	[1 - 3]
quickRatioTTM	1.503	0.800	5.87	4.69	[0.8 - 2.5]
cashRatioTTM	0.639	1.500	7.56	10.00	[0.2 - 2]
debtRatioTTM	0.318	-1.500	4.70	-7.04	[0 - 0.6]
interestCoverageTTM	-2.03	1.000	-1.862	-1.862	[3 - 30]
operatingCashFlowPerShareTTM	8.12	2.00	7.29	10.00	[0 - 30]
freeCashFlowPerShareTTM	7.55	2.00	6.23	10.00	[0 - 20]
debtEquityRatioTTM	0.586	-1.500	7.66	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.610	1.000	3.16	3.16	[0.2 - 0.8]
operatingProfitMarginTTM	-0.0438	1.000	-2.88	-2.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.185	1.000	-0.0812	-0.0812	[0.2 - 2]
assetTurnoverTTM	0.287	0.800	-1.420	-1.136	[0.5 - 2]
Total Score				7.61

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	587.03	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00241	2.50	-0.697	-1.626	[0.1 - 1.5]
freeCashFlowPerShareTTM	7.55	2.00	7.48	10.00	[0 - 30]
dividendYielPercentageTTM	0.620	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.12	2.00	7.29	10.00	[0 - 30]
payoutRatioTTM	3.63	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	1.693	1.500	2.05	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.206	1.000	7.36	0	[0.1 - 0.5]
Total Score				5.87

Mesa Laboratories Inc

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.